203 related articles for article (PubMed ID: 38449562)
21. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.
Oh DY; Ruth He A; Qin S; Chen LT; Okusaka T; Vogel A; Kim JW; Suksombooncharoen T; Ah Lee M; Kitano M; Burris H; Bouattour M; Tanasanvimon S; McNamara MG; Zaucha R; Avallone A; Tan B; Cundom J; Lee CK; Takahashi H; Ikeda M; Chen JS; Wang J; Makowsky M; Rokutanda N; He P; Kurland JF; Cohen G; Valle JW
NEJM Evid; 2022 Aug; 1(8):EVIDoa2200015. PubMed ID: 38319896
[TBL] [Abstract][Full Text] [Related]
22. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK; Ueno M; Yoo C; Finn RS; Furuse J; Ren Z; Yau T; Klümpen HJ; Chan SL; Ozaka M; Verslype C; Bouattour M; Park JO; Barajas O; Pelzer U; Valle JW; Yu L; Malhotra U; Siegel AB; Edeline J; Vogel A;
Lancet; 2023 Jun; 401(10391):1853-1865. PubMed ID: 37075781
[TBL] [Abstract][Full Text] [Related]
23. Futibatinib for
Goyal L; Meric-Bernstam F; Hollebecque A; Valle JW; Morizane C; Karasic TB; Abrams TA; Furuse J; Kelley RK; Cassier PA; Klümpen HJ; Chang HM; Chen LT; Tabernero J; Oh DY; Mahipal A; Moehler M; Mitchell EP; Komatsu Y; Masuda K; Ahn D; Epstein RS; Halim AB; Fu Y; Salimi T; Wacheck V; He Y; Liu M; Benhadji KA; Bridgewater JA;
N Engl J Med; 2023 Jan; 388(3):228-239. PubMed ID: 36652354
[TBL] [Abstract][Full Text] [Related]
24. EZH2 Promotes Cholangiocarcinoma Development and Progression through Histone Methylation and microRNA-Mediated Down-Regulation of Tumor Suppressor Genes.
Zhang J; Chen W; Ma W; Han C; Song K; Kwon H; Wu T
Am J Pathol; 2022 Dec; 192(12):1712-1724. PubMed ID: 36456043
[TBL] [Abstract][Full Text] [Related]
25. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA).
Ioka T; Kanai M; Kobayashi S; Sakai D; Eguchi H; Baba H; Seo S; Taketomi A; Takayama T; Yamaue H; Takahashi M; Sho M; Kamei K; Fujimoto J; Toyoda M; Shimizu J; Goto T; Shindo Y; Yoshimura K; Hatano E; Nagano H;
J Hepatobiliary Pancreat Sci; 2023 Jan; 30(1):102-110. PubMed ID: 35900311
[TBL] [Abstract][Full Text] [Related]
27. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
[TBL] [Abstract][Full Text] [Related]
28. Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer.
Doki Y; Ueno M; Hsu CH; Oh DY; Park K; Yamamoto N; Ioka T; Hara H; Hayama M; Nii M; Komuro K; Sugimoto M; Tahara M
Cancer Med; 2022 Jul; 11(13):2550-2560. PubMed ID: 35611499
[TBL] [Abstract][Full Text] [Related]
29. EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.
Wu Q; Zhen Y; Shi L; Vu P; Greninger P; Adil R; Merritt J; Egan R; Wu MJ; Yin X; Ferrone CR; Deshpande V; Baiev I; Pinto CJ; McLoughlin DE; Walmsley CS; Stone JR; Gordan JD; Zhu AX; Juric D; Goyal L; Benes CH; Bardeesy N
Cancer Discov; 2022 May; 12(5):1378-1395. PubMed ID: 35420673
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.
Oh DY; Lee KH; Lee DW; Yoon J; Kim TY; Bang JH; Nam AR; Oh KS; Kim JM; Lee Y; Guthrie V; McCoon P; Li W; Wu S; Zhang Q; Rebelatto MC; Kim JW
Lancet Gastroenterol Hepatol; 2022 Jun; 7(6):522-532. PubMed ID: 35278356
[TBL] [Abstract][Full Text] [Related]
31. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers.
Yarchoan M; Cope L; Ruggieri AN; Anders RA; Noonan AM; Goff LW; Goyal L; Lacy J; Li D; Patel AK; He AR; Abou-Alfa GK; Spencer K; Kim EJ; Davis SL; McRee AJ; Kunk PR; Goyal S; Liu Y; Dennison L; Xavier S; Mohan AA; Zhu Q; Wang-Gillam A; Poklepovic A; Chen HX; Sharon E; Lesinski GB; Azad NS
J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34907910
[TBL] [Abstract][Full Text] [Related]
32. Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma.
Wu MJ; Shi L; Dubrot J; Merritt J; Vijay V; Wei TY; Kessler E; Olander KE; Adil R; Pankaj A; Tummala KS; Weeresekara V; Zhen Y; Wu Q; Luo M; Shen W; García-Beccaria M; Fernández-Vaquero M; Hudson C; Ronseaux S; Sun Y; Saad-Berreta R; Jenkins RW; Wang T; Heikenwälder M; Ferrone CR; Goyal L; Nicolay B; Deshpande V; Kohli RM; Zheng H; Manguso RT; Bardeesy N
Cancer Discov; 2022 Mar; 12(3):812-835. PubMed ID: 34848557
[TBL] [Abstract][Full Text] [Related]
33. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
Yoo C; Kim KP; Jeong JH; Kim I; Kang MJ; Cheon J; Kang BW; Ryu H; Lee JS; Kim KW; Abou-Alfa GK; Ryoo BY
Lancet Oncol; 2021 Nov; 22(11):1560-1572. PubMed ID: 34656226
[TBL] [Abstract][Full Text] [Related]
34. Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
Valle JW; Vogel A; Denlinger CS; He AR; Bai LY; Orlova R; Van Cutsem E; Adeva J; Chen LT; Obermannova R; Ettrich TJ; Chen JS; Wasan H; Girvan AC; Zhang W; Liu J; Tang C; Ebert PJ; Aggarwal A; McNeely SC; Moser BA; Oliveira JM; Carlesi R; Walgren RA; Oh DY
Lancet Oncol; 2021 Oct; 22(10):1468-1482. PubMed ID: 34592180
[TBL] [Abstract][Full Text] [Related]
35. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Javle M; Roychowdhury S; Kelley RK; Sadeghi S; Macarulla T; Weiss KH; Waldschmidt DT; Goyal L; Borbath I; El-Khoueiry A; Borad MJ; Yong WP; Philip PA; Bitzer M; Tanasanvimon S; Li A; Pande A; Soifer HS; Shepherd SP; Moran S; Zhu AX; Bekaii-Saab TS; Abou-Alfa GK
Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):803-815. PubMed ID: 34358484
[TBL] [Abstract][Full Text] [Related]
36. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.
Javle M; Borad MJ; Azad NS; Kurzrock R; Abou-Alfa GK; George B; Hainsworth J; Meric-Bernstam F; Swanton C; Sweeney CJ; Friedman CF; Bose R; Spigel DR; Wang Y; Levy J; Schulze K; Cuchelkar V; Patel A; Burris H
Lancet Oncol; 2021 Sep; 22(9):1290-1300. PubMed ID: 34339623
[TBL] [Abstract][Full Text] [Related]
37. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead.
Kirtane K; Elmariah H; Chung CH; Abate-Daga D
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301811
[TBL] [Abstract][Full Text] [Related]
38. Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.
Song X; Xu H; Wang P; Wang J; Affo S; Wang H; Xu M; Liang B; Che L; Qiu W; Schwabe RF; Chang TT; Vogl M; Pes GM; Ribback S; Evert M; Chen X; Calvisi DF
J Hepatol; 2021 Oct; 75(4):888-899. PubMed ID: 34052254
[TBL] [Abstract][Full Text] [Related]
39. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.
Lamarca A; Palmer DH; Wasan HS; Ross PJ; Ma YT; Arora A; Falk S; Gillmore R; Wadsley J; Patel K; Anthoney A; Maraveyas A; Iveson T; Waters JS; Hobbs C; Barber S; Ryder WD; Ramage J; Davies LM; Bridgewater JA; Valle JW;
Lancet Oncol; 2021 May; 22(5):690-701. PubMed ID: 33798493
[TBL] [Abstract][Full Text] [Related]
40. Clinical Trial of a Cancer Vaccine Targeting VEGF and KIF20A in Advanced Biliary Tract Cancer.
Murahashi M; Tsuruta T; Yamada K; Hijikata Y; Ogata H; Kishimoto J; Yoshimura S; Hikichi T; Nakanishi Y; Tani K
Anticancer Res; 2021 Mar; 41(3):1485-1496. PubMed ID: 33788741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
